McMaster University Identifies Antibiotic 'Megacluster' in Streptomyces

By Rachel Kim

Researchers at McMaster University have discovered an antibiotic 'megacluster' in Streptomyces bacteria, which could pave the way for new treatments against drug-resistant infections. The study, published in Nature, reveals that this megacluster comprises four co-located biosynthetic gene clusters and streptavidin genes, collectively targeting bacterial biotin metabolism.

The megacluster encodes the production of four distinct natural product families: stravidins, acidomycins, dapamycins, and α-Me-KAPA, along with streptavidin, a high-affinity biotin-binding protein. These agents work synergistically to disrupt biotin biosynthesis, uptake, and function through enzyme inhibition, prodrug activation, cofactor mimicry, and sequestration.

In vivo experiments using a mouse model of multidrug-resistant E. coli infection demonstrated the enhanced efficacy of the combination of stravidin S2 and α-Me-KAPA, achieving up to a 99% reduction in bacterial load in blood, liver, kidneys, and spleen.

The full gene cluster spans at least 65,808 base pairs and was successfully cloned to produce the antibiotic cocktail in a laboratory Streptomyces strain. The megacluster is evolutionarily conserved and widespread across multiple Streptomyces species, even more so than the classic streptomycin biosynthetic genes.